Makale detayı · 2022
Analysis of Biomarkers and Marginal Bone Loss in Platform-Switched and Nonplatform-Switched Implants: A Randomized Clinical Trial
- Yıl
- 2022
- ISSN
2314-6133- Tür
- article
Veri kaynağı ayrımı
- YÖKSİS YÖKSİS makale kaydı
- OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)
Özet
İngilizce (OpenAlex)
Objectives. To compare the peri‐implant crevicular fluid (PICF) biomarker levels, peri‐implant status, and marginal bone level (MBL) differences of implants restored with randomly assigned nonplatform‐switched (NPS) or platform‐switched (PS) abutments. Methods. Ninety‐four implants in 27 subjects were included in this study. Receptor activator of nuclear factor kappa‐B ligand (RANKL), osteoprotegerin (OPG), interleukin‐1β (IL‐1β), monocyte chemotactic protein‐1 (MCP‐1) levels in PICF, peri‐implant health, and the change in the MBL were evaluated at the time of restoration (T1) and after 12 months (T2). Results. The IL‐1β levels decreased and the RANKL, OPG, and MCP‐1 levels increased from T1 to T2 (P < 0.05) in both groups. RANKL/OPG ratio at T1, MCP‐1 levels at T2, and the MCP‐1 change from T1 to T2 were lower in the PS group than in the NPS group (P < 0.05). MBL change was lower (0.51 ± 0.31 mm) in the PS group than that (0.75 ± 0.29 mm) in the NPS group at T2 (P < 0.001). Peri‐implant health status between the study groups was negligible. Conclusion. PS was superior to NPS regarding the preservation of MBL. Higher MCP‐1 levels, altered RANKL/OPG ratio, and lower OPG levels in the NPS group could be associated with subclinical peri‐implant bone remodeling.
Konular
- Dental Implant Techniques and Outcomes
- Bone Tissue Engineering Materials
- Periodontal Regeneration and Treatments
Birincil konu Dental Implant Techniques and Outcomes